Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Sponsor: Stanford University
This observational or N/A phase trial investigates Epidermolysis Bullosa Dystrophica and is currently actively recruiting participants. Stanford University leads this study, which shows 16 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)We will obtain a detailed medical history and will perform a skin examination and brief physical exam. Photographs may be taken. We will ask questions about the size and duration wounds.
LAB TESTS We will draw blood to determine overall health status to include Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) testing. Genetic testing may also be performed.
BIOPSIES Biopsies may be collected to check for Collagen 7 and for antibodies to Collagen 7.
Based on the results obtained, it may be possible to identify patients who would qualify to participate in current or future clinical trials.
We will obtain a detailed medical history and will perform a skin examination and brief physical exam. Photographs may be taken. We will ask questions about the size and duration wounds.
LAB TESTS We will draw blood to determine overall health status to include Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) testing. Genetic testing may also be performed.
BIOPSIES Biopsies may be collected to check for Collagen 7 and for antibodies to Collagen 7.
Based on the results obtained, it may be possible to identify patients who would qualify to participate in current or future clinical trials.
Status Flow
Change History
16 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
-
Jan 2025 — Apr 2026 [monthly]
Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 11 earlier versions
-
Nov 2022 — Dec 2023 [monthly]
Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Recruiting
-
Apr 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Aug 2018 — Nov 2020 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Status: Recruiting → Unknown Status · Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Contact Information
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .